Progyny, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.3B | $1.2B | $1.1B | $786.9M | $500.6M |
| Cost of revenue | $984.2M | $913.9M | $849.8M | $619.6M | $388.5M |
| Gross profit | $304.5M | $253.4M | $238.8M | $167.3M | $112.1M |
| Research and development | $9.5M | — | — | — | — |
| Operating expenses | $219.2M | $185.9M | $176.6M | $144.0M | $79.8M |
| Operating income | $85.3M | $67.5M | $62.2M | $23.3M | $32.3M |
| Pretax income | $95.4M | $83.2M | $70.7M | $24.4M | $32.4M |
| Income tax expense | $36.9M | $28.9M | $8.7M | -$5.9M | -$33.3M |
| Net income | $58.5M | $54.3M | $62.0M | $30.4M | $65.8M |
| Balance Sheet | |||||
| Cash and equivalents | $112.2M | $162.3M | $97.3M | $120.1M | $91.4M |
| Current assets | $551.8M | $472.7M | $640.4M | $433.9M | $258.5M |
| Total assets | $742.4M | $607.1M | $756.6M | $543.0M | $358.1M |
| Current liabilities | $202.4M | $168.6M | $185.9M | $159.5M | $98.8M |
| Total liabilities | $226.4M | $185.0M | $203.2M | $166.0M | $106.2M |
| Stockholders' equity | $516.0M | $422.1M | $553.4M | $377.0M | $251.8M |
| Cash Flow Statement | |||||
| Cash from operations | $210.2M | $179.1M | $188.8M | $80.4M | $26.0M |
| Depreciation and amortization | $4.9M | $3.2M | $2.3M | $1.6M | $1.3M |
| Stock-based compensation | $131.9M | $128.1M | $122.6M | $100.7M | $33.7M |
| Capital expenditure | $18.4M | $5.4M | $3.6M | $3.2M | $2.1M |
| Free cash flow | $191.8M | $173.7M | $185.2M | $77.2M | $23.9M |
| Share repurchases | $81.7M | $300.3M | $0 | $0 | — |
| Impairments | — | $0 | $0 | $0 | $0 |
Shares outstanding 78.3M · Free float 69.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.